Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. 

For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. 

Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. 

Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. 

(BSE)